Geron (GERN) Assets Average (2011 - 2026)
Geron's (GERN) quarterly Assets Average came in at $526.6 million in Q2 2026, down 5.77% year-over-year from $558.8 million in Q2 2025, and down 4.66% quarter-over-quarter from $552.3 million in Q1 2026.
Analysis
Geron (GERN) Assets Average (2011 - 2026) Analysis & Trends
Geron has disclosed Assets Average across 16 years of filings, most recently posting $526.6 million for Q2 2026.
- In Q2 2026, Assets Average fell 5.77% year-over-year to $526.6 million; the TTM figure through Jun 2026 stood at $526.6 million (down 5.77% YoY), while the FY2025 annual figure was $582.2 million, up 17.86% from the prior year.
- Assets Average came in at $526.6 million for Q2 2026 at Geron, down from $552.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $578.1 million in Q1 2025 to a low of $211.6 million in Q4 2022.
- Average Assets Average over 5 years is $424.4 million, with a median of $442.6 million recorded in 2024.
- Year-over-year, Assets Average dropped 19.81% in 2022 and surged 92.44% in 2023.
- Over 5 years, Assets Average stood at $211.6 million in 2022, then jumped by 90.72% to $403.5 million in 2023, then advanced by 28.7% to $519.4 million in 2024, then increased by 9.55% to $569.0 million in 2025, then decreased by 7.45% to $526.6 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $526.6 million in Q2 2026, $552.3 million in Q1 2026, and $569.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 526.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 526.56 Mn |
| Mar 31, 2026 | 552.33 Mn |
| Dec 31, 2025 | 568.96 Mn |
| Sep 30, 2025 | 561.29 Mn |
| Jun 30, 2025 | 558.82 Mn |
| Mar 31, 2025 | 578.12 Mn |
| Dec 31, 2024 | 519.37 Mn |
| Sep 30, 2024 | 447.17 Mn |
| Jun 30, 2024 | 465.74 Mn |
| Mar 31, 2024 | 438.08 Mn |
| Dec 31, 2023 | 403.55 Mn |
| Sep 30, 2023 | 414.16 Mn |
| Jun 30, 2023 | 420.09 Mn |
| Mar 31, 2023 | 307.73 Mn |
| Dec 31, 2022 | 211.59 Mn |
| Sep 30, 2022 | 235.38 Mn |
| Jun 30, 2022 | 218.29 Mn |
| Mar 31, 2022 | 212.23 Mn |
| Dec 31, 2021 | 227.57 Mn |
| Sep 30, 2021 | 240.64 Mn |